People: Amarin Corporation PLC (AMRN.OQ)
19 Jun 2019
Dr. Stephen B. Ketchum, Ph.D., is President - Research and Development, Senior Vice President, Chief Scientific Officer of Amarin Corp Plc. Dr. Ketchum has a significant record of achievement in the life sciences industry, with 20 years of experience in late-stage product development and clinical regulatory strategy, having led the filings of multiple successful new drug applications (NDAs) and supplemental NDAs. Prior to joining Amarin, Dr. Ketchum served as senior vice president, research and development for Sunesis Pharmaceuticals where, as a member of the Executive Committee, he provided strategic direction for all facets of research and development, including clinical strategy and operations, regulatory affairs, and pharmaceutical development. Prior to Sunesis, Dr. Ketchum was senior vice president, research and development and medical affairs at Reliant Pharmaceuticals with responsibilities for leading the strategic direction and day-to-day operations of Reliant's clinical research, product development, and medical affairs departments, including responsibilities for Lovaza, an earlier generation prescription omega-3 drug. Dr. Ketchum has also served as senior vice president, operations and regulatory affairs for IntraBiotics Pharmaceuticals, Inc., where he was responsible for regulatory affairs, project management, quality assurance, and supply chain management in support of late-stage clinical research.
|Total Annual Compensation, USD||523,342|
|Restricted Stock Award, USD||345,780|
|Long-Term Incentive Plans, USD||--|
|All Other, USD||329,468|
|Fiscal Year Total, USD||1,198,590|